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Background: Secretagogin (Scgn), a member of the EF-hand calcium-binding protein (CaBP) superfamily, has
recently been found in subsets of developing and adult neurons. Here, we have analyzed the expression of Scgn in
dorsal root ganglia (DRGs) and trigeminal ganglia (TGs), and in spinal cord of mouse at the mRNA and protein
levels, and in comparison to the well-known CaBPs, calbindin D-28k, parvalbumin and calretinin. Rat DRGs, TGs and
spinal cord, as well as human DRGs and spinal cord were used to reveal phylogenetic variations.
Results: We found Scgn mRNA expressed in mouse and human DRGs and in mouse ventral spinal cord. Our
immunohistochemical data showed a complementary distribution of Scgn and the three CaBPs in mouse DRG
neurons and spinal cord. Scgn was expressed in ~7% of all mouse DRG neuron profiles, mainly small ones and
almost exclusively co-localized with calcitonin gene-related peptide (CGRP). This co-localization was also seen in
human, but not in rat DRGs. Scgn could be detected in the mouse sciatic nerve and accumulated proximal to its
constriction. In mouse spinal cord, Scgn-positive neuronal cell bodies and fibers were found in gray matter,
especially in the dorsal horn, with particularly high concentrations of fibers in the superficial laminae, as well as in
cell bodies in inner lamina II and in some other laminae. A dense Scgn-positive fiber network and some small cell
bodies were also found in the superficial dorsal horn of humans. In the ventral horn, a small number of neurons
were Scgn-positive in mouse but not rat, confirming mRNA distribution. Both in mouse and rat, a subset of TG
neurons contained Scgn. Dorsal rhizotomy strongly reduced Scgn fiber staining in the dorsal horn. Peripheral
axotomy did not clearly affect Scgn expression in DRGs, dorsal horn or ventral horn neurons in mouse.
Conclusions: Scgn is a CaBP expressed in a subpopulation of nociceptive DRG neurons and their processes in the
dorsal horn of mouse, human and rat, the former two co-expressing CGRP, as well as in dorsal horn neurons in all
three species. Functional implications of these findings include the cellular refinement of sensory information, in
particular during the processing of pain.
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Calcium-binding proteins (CaBPs) play a major role in
neuronal functions, and their cellular distribution in the
nervous system has in many cases been thoroughly
mapped by immunohistochemistry [1,2]. In particular,
parvalbumin (PV), calretinin (CR) and calbindin D-28k
(CB) have received much attention due to their robust,
developmentally regulated and cell type-specific expres-
sion in the nervous system, and have emerged as effect-
ive markers to identify subpopulations of neurons [2-4].
In general terms, these proteins act either as Ca2+ sen-
sors or buffers of Ca2+ transients in neurons, defined by
their molecular properties and the signaling context they
participate in [5]. Chemically, CaBPs are characterized
by a tandem repeat of the Ca2+-binding loop surrounded
by two helices, the EF-hand binding site [1,6,7].
Secretagogin (Scgn) is a recently cloned member of
the EF-hand CaBP superfamily, first identified from a
human pancreatic cDNA library by immunoscreening
with the murine monoclonal antibody D24 generated
using human insulinoma as immunogen [8,9]. Structur-
ally, Scgn’s deduced amino acid sequence specifies a pro-
tein of 276 amino acids with a calculated molecular
mass of 32 kDa that can bind up to four Ca2+ ions sim-
ultaneously [8]. Using immunohistochemical method-
ology, Scgn has been detected in several tissues, such as
the brain of various mammalian species including
humans [10-16], where it may associate with SNAP-25
[17], a protein(s) participating in the vesicular exocytosis
of neurotransmitters [18], possibly neurodegeneration
[10-12], as well as development, including embryonic ex-
pression in dorsal root ganglia (DRGs) and trigeminal
ganglia (TGs) [15].
DRGs are composed of a considerable number of
neuronal subtypes underpinning specific sensory modal-
ities, and all originating from a common pool of embry-
onic precursors [19,20]. As in other neuronal systems
(see above), CaBPs have been used as markers in numer-
ous studies reporting the distribution of CaBPs in sen-
sory ganglia at different levels. In particular, DRGs and
TGs have been extensively analyzed. In addition, the
spinal dorsal horn and spinal trigeminal nucleus, regions
important for sensory information processing, including
pain, have been studied. They include chicken [21-23],
Xenopus laevis [24], turtle [25], zebra fish [26], dog [27],
mouse [28-32] and, most thoroughly, rat [2,21,33-50].
However, caveats of knowledge exist regarding the cellu-
lar sites of Scgn mRNA expression and protein distribu-
tion in DRGs or spinal cord.
In the present study we have therefore analyzed, with
quantitative (real-time) PCR (qPCR), in situ hybridization
and high-resolution immunohistochemistry, the localization
of Scgn in mouse DRGs (mDRGs) and spinal cord, with
emphasis on its possible co-localization with PV, CR, andCB, as well as with calcitonin gene-related peptide (CGRP)
or isolectin B4 (IB4), classic markers of nociceptive neurons
[51,52]. In addition, the presence of three further molecules
known to be expressed in DRGs/dorsal horn was studied:
transient receptor potential vanilloid subtype 1 (TRPV1)
[53], gastrin releasing peptide (GRP) [54-56], and protein
kinase C gamma (PKCgamma) [57]. Dorsal root transection
and unilateral peripheral sciatic nerve injury were per-
formed in mice. Finally, we have, in a preliminary way,
studied the extent of phylogenetic conservation in Scgn’s
distribution by comparing mouse DRGs, TGs and spinal
cord with rat DRGs (rDRGs), rat TGs (rTGs) and rat
spinal cord, as well as with human DRGs (hDRGs) and
spinal cord. Some of these results were presented in a pre-
liminary form at the 13th World Congress on Pain [58].
Results
Scgn mRNA detection: methodological considerations and
tissue distribution pattern
Recently, Scgn has been localized in the brain with
immunohistochemistry using affinity-purified antibodies
raised against distinct peptide domains (“epitopes”) of
this protein [15], producing results that correspond well
with publicly-available mRNA distribution maps [59].
Nevertheless, correlative analysis of Scgn mRNA and
protein has not been performed. Therefore, we first
probed Scgn mRNA distribution in the olfactory bulb,
containing highest Scgn protein and mRNA levels in the
nervous system [15,16]. We visualized, using riboprobes,
Scgn mRNA as a “band” in deep neurons populating the
granular layer (Additional file 1: Figure S1A), as well as
the inner sublayer of the external plexiform layer
(Additional file 1: Figure S1A1). In addition, Scgn
mRNA, though at relatively low levels, was found in cells
scattered around olfactory glomeruli Additional file 1:
Figure S1A2,B), likely periglomerular interneurons. Thus,
corresponding Scgn mRNA (Additional file 1: Figure
S1A-A2) and protein distribution patterns (Additional file
1: Figure S1C,C1) support the specificity of the antibodies
used in the present and previous [15,16,60] studies.
Next, we profiled relative Scgn mRNA levels between
amongst mouse olfactory bulb, dorsal and ventral spinal
cord, and DRGs lumbar 4 and 5 (L4-5) by means of
qPCR. While Scgn mRNA levels in the olfactory bulb
were exceptionally high (Figure 1a), they were under de-
tection threshold and at very low levels in the dorsal and
ventral spinal horns, respectively (Figure 1a). Moderate
Scgn mRNA levels were detected in DRGs (Figure 1a, n
= 3/region) suggesting that only a restricted population
of DRG neurons might be Scgn immunoreactive (IR).
We also addressed Scgn expression in DRGs using in
situ hybridization. We demonstrate, by using oligoprobes,
that a small population of cells in the hDRG expresses
notable levels of Scgn mRNA (Figure 1b,c). However, we
Figure 1 Scgn expression in DRGs. (a) Quantitative (real-time) PCR detection of Scgn mRNA in mouse olfactory bulb (OB), ventral and dorsal
horns (VH/DH) of L4-5 spinal cord segments, and L4-5 DRGs. Scgn mRNA is found expressed at significantly lower levels in VH and DRGs than in
the OB. Scgn mRNA is under the detection threshold in DH. Gapdh is used as internal control. (b-c) Scgn mRNA expression in human DRG
(hDRG). Semitransparent purple and green shades outline the surface area of Scgn mRNA-positive and negative cells, respectively. Note that
tissues are counterstained by cresyl violet after emulsion-radiography of the mRNA hybridization signal. Scgn-LI in control L5 mDRGs (d-m”).
Immunofluorescence micrographs of sections incubated with antiserum to Scgn (d-m), CGRP (f’), IB4 (g’), TRPV1 (h’), GRP (i’), NF200 (j’), CB (k’),
PV (l’) or CR (m’). Color micrographs show merged micrographs after double-staining (f-f”, g-g”, h-h”, i-i”, j-j”, k-k”, l-l”, m-m” show, respectively,
the same section). (d) Several Scgn-IR cells are seen. Boxed area shows Scgn staining also in the nucleus. Arrowheads indicate Scgn-positive
fibers. (e) Double labeling shows the same staining pattern present after incubation with two different Scgn antibodies (arrowheads). (f-m”)
Arrowheads indicate coexistence of Scgn (yellow) with CGRP (f-f”), TRPV1 (h-h”), NF200 (j-j”) and CR (m-m”), most pronounced for Scgn plus
CGRP (f-f”). Scgn-LI cannot be seen in IB4-positive (g-g”), GRP (i-I”), CB-(k-k”) or PV-IR (l-l”) neurons. Scale bars indicate 10 μm (b,c), 50 μm (d,e-
m”).
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mDRGs, probably reflecting the sparse mRNA levels
found in our qPCR analysis.
Expression of Scgn protein in neurons in DRGs
In adult mDRGs, 7.3±1.2% of all neuron profiles (NPs)
were Scgn-IR (Figure 1d), including nuclear-like Scgn dis-
tribution in some mDRG neurons (Figure 1d and inset).
Only few and weakly fluorescent processes were detected
in the DRGs (Figure 1d). Most Scgn-IR NPs (73%) were
small-sized (Figure 1d). The same staining pattern was
observed after incubation with a rabbit anti-human Scgn
antibody raised against a different epitope revealing
double-labeled (identical) cell bodies (Figure 1e). In
mDRGs, Scgn-IR neurons abundantly expressed CGRP(98.0±3.4%) (Figure 1f-f"), a phenotypic marker for pepti-
dergic neurons, whereas none of the Scgn-IR neuron co-
localized with IB4 (Figure 1g-g"), a marker for non-
peptidergic neurons. TRPV1-like immunoreactivity (LI)
was found in 20.0±2.5% of all Scgn-IR NPs (Figure 1h-h").
In contrast, Scgn- and GRP-LIs did not co-exist
(Figure 1i-i´´). Very few of the Scgn-IR neurons in mouse
expressed NF200-LI (Figure 1j-j´´).
Scgn expression in mDRGs was compared with those
of the three “classical” CaBPs using double-label immu-
nohistochemistry (that is PV, CB and CR). Scgn revealed
a separate neuron population, only occasionally
expressed in NPs immunoreactive for CB (0.5±0.5%;
Figure 1k-k´´), PV (0.4±0.4%; Figure 1l-l´´), although
some expressed CR (2.1±1.3%; Figure 1m-m´´).
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mainly small-sized (Figure 2a-e). None of the Scgn-IR
neurons co-expressed CGRP (Figure 2a), contrasting
mouse, or IB4 (Figure 2b). With regard to coexistence
with the three CaBPs, 42.5±2.2% of the Scgn-IR NPs
were CB-IR (Figure 2c). Neither PV nor CR-IR NPs were
Scgn-positive (Figure 2d,e).
In the hDRGs, 13.3±0.4% of all NPs were Scgn-IR
(Figure 3a), and there were also distinct processes
(Figure 3e,g). Of the Scgn-IR NPs, 94.1±3.6% were
CGRP-IR (Figure 3b-d), but no IB4-positive ones were
detected (Figure 3e-g). 12.3±3.8% of CGRP-IR NPs
expressed Scgn (Figure 3b-d).
In mTGs 5.9±0.5% NPs were Scgn-positive, and 91.7±
1.9% of Scgn-IR NPs coexpressed CGRP (Figure 4a),
whereas no Scgn-positive NPs expressed IB4 (Figure 4b).
In rTGs, 80.5±7.9% and 75.3±9.5% of Scgn-IR NPs were
CGRP- and IB4-IR, respectively (Figure 4c,d).
Localization of Scgn protein in spinal cord and sciatic
nerve
Scgn-LI was found both in the neuronal cell bodies and
fibers/processes in the mouse spinal cord: Scgn-IR fibers
formed a dense plexus in the superficial dorsal horn
(Lissauer’s tract) (Figures 5a,b; 6a). Scgn-IR neurons were
mainly found in inner lamina II (Figures. 5c; 6a), but some
cells were also seen in layers II-V, including both small
neurons (Figure 5f) and large, multipolar neurons
(Figure 5d,e). In the ventral horn, Scgn-positive neurons
were sporadically seen (Figure 5g), and some of them
(3.0%) co-expressed CGRP (Figure 5g-i), in this region a
marker for motoneurons [61].
In mouse dorsal horn, using double staining, we detected
most superficial Scgn-IR fibers were CGRP-IR (Figure 6a-c),
however, the CGRP-IR fibers extended deeper than the
Scgn-positive ones (Figure 6a-c). The Scgn-positive inter-
neurons and fibers lacked TRPV1-LI (Figure 5j-j´´). None
of the Scgn-positive fibers or neuronal cell bodies were
GRP-IR (Figure 5k,k´), nor were Scgn-positive neuronal
cell bodies in lamina II PKCgamma-positive (Figure 5l,l´).a b c
Figure 2 Scgn-LI in control L5 rDRGs. (a-e) Double-immunofluorescence
green) plus CGRP (a; red), IB4 (b; red), CB (c; red), PV (d; red) or CR (e; red).
indicates 50 μm (a-e).Scgn-LI was present in some CB-IR neurons (Figure 5m,m´),
in very few PV-IR (Figure 5n,o) and CR-IR neurons
(Figure 5p,q). The neuron in Figure 5r and r´ expressing
Scgn and CB appeared PV-negative. There were also neu-
rons co-expressing Scgn and CB but apparently not CR
(Figure 5s,t).
Unilateral dorsal rhizotomy strongly reduced both Scgn-
and CGRP-LIs in the superficial region of the ipsilateral
dorsal horn as compared to the contralateral side (cf.
Figure 6a-c with d-f). However, there were still cell bodies
and processes in inner lamina II (Figure 6d,f). In the sci-
atic nerve, a moderate number of Scgn-IR axons could be
seen (Figure 6g), however fewer than the CGRP-positive
ones (Figure 6h), partially overlapping (Figure 6i). Ten
hours after ligation of the sciatic nerve there was distinct
accumulation of Scgn-LI (Figure 6j) and CGRP-LI
(Figure 6k) proximal to the site of the injury. In contrast
to the normal nerve, there seemed to be a more equal
number of fibers immunoreactive for Scgn and CGRP
with prominent overlap, further supporting their co-
existence (Figure 6l).
In the rat dorsal horn, Scgn-LI was less prominent and
mainly observed in medial, inner lamina II (Figure 7a,d),
partly overlapping with CGRP-IR fibers (Figure 7b,c) and
with IB4 (Figure 7e,f) stainings. There was a moderate
number of small Scgn-IR cell bodies in laminae I-IV
(Figure 7a,d). Double-staining experiments showed that, in
the rat superficial dorsal horn, some Scgn-IR neurons
expressed CB- (Figure 7g-i) or PV- (Figure 7j-l), but not
CR (Figure 7m-o). In contrast to mouse, Scgn-LI was not
found in rat ventral horn neurons (data not shown).
In the human spinal cord, a dense network of Scgn-IR
fibers was observed in the superficial, especially lateral,
dorsal horn, most of which were CGRP-IR (Figure 3h-j).
As in mouse, the CGRP fibers extended ventrally beyond
the Scgn zone. A few Scgn-positive cell bodies, surrounded
by Scgn nerve endings were seen in inner lamina II, but
they did not, as in mouse, from a distinct band (Figure
3k-m). Scgn-IR/CGRP-IR axons were also observed in ac-
cidentally included dorsal roots (Figure 3n-p).d e
micrographs of sections incubated with antiserum to Scgn (a-e;
Arrows indicate coexistence of Scgn with CB (c; yellow). Scale bar
Figure 3 Scgn-LI in hDRG and human spinal cord. (a-d) Immunofluorescence micrographs of section incubated with antiserum against Scgn
(a,b,d) or/and CGRP (c,d). (b-d) show same section processed for double-immunofluorescence. Arrowheads indicate Scgn-IR neurons (a), and
neurons co-expressing (solid arrowheads in d; yellow) Scgn- (b, d) and CGRP-LI (c, d). Note that all Scgn-IR neurons are CGRP-IR. (e-g)
Immunofluorescence micrographs of section incubated with antiserum against Scgn (e, g) or/and IB4 (f, g). e-g show same section processed for
double-immunofluorescence. Arrowheads indicate Scgn-IR fibers (e, g). Note that no Scgn-IR neuron is IB4-positive. (h-p) Immunofluorescence
micrographs of a section incubated with antiserum against Scgn (h,j,k,m,n and p) or/and CGRP (i,j,l,m,o and p). h-j show the double-labeling of
Scgn and CGRP in human spinal cord at low magnification. Scgn-IR fibers are concentrated in the lateral superficial layer and some of them show
co-localization with CGRP as indicated by arrowheads (inset in j). k-m show Scgn-IR interneurons surrounded by some positive nerve endings in
inner layer of lamina II (arrowheads indicate Scgn-IR interneurons). n-p show the co-localization of Scgn-LI and CGRP-LI in axons in the dorsal
roots (arrowheads, yellow). Scale bars indicate 200 μm (a, h-j), 100 μm (b-g), 20 μm (k-m, n-p and inset in j).
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Transection of the sciatic nerve did not significantly
affect the percentage of Scgn-IR NPs in ipsilateral mouse
DRGs as compared to contralateral ones (6.6±1.0% vs.
6.3±0.9; P>0.05). In agreement, Western blotting showed
no change of Scgn protein levels in ipsilateral vs. contra-
lateral mDRGs (Figure 8a). Finally, in mouse spinal cord,the total protein levels of Scgn did not change after per-
ipheral nerve injury (Figure 8b).
Discussion
The present study shows that Scgn, a recently identified
member of the CaBP superfamily [8], is expressed in dis-
tinct neuronal populations at the spinal level of several
a  b  
c  d  
Figure 4 Scgn-LI in mTG and rTG. (a-d) Immunofluorescence micrographs showing mTG (a,b) and rTG (c,d) after double-staining with
antiserum against Scgn (a-d; green) and CGRP (a,c; red) or IB4 (b,d; red). Arrows indicate coexistence of Scgn (yellow) with CGRP (a,c) or IB4 (d).
Note coexistence of Scgn with CGRP in m- and rTGs, and of Scgn with IB4 in rTG but not in mTG. Scale bars indicate 50 μm (a=b; c=d).
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neurons express CGRP (98%)- and TRPV1-(~20%) but
are IB4-negative [51,52]. Thus, the TRPV1-IR population
of these neurons may be sensitive to noxious heat [53].
The apparent lack of GRP in Scgn-IR DRG neurons
indicates that they are not involved in itching [56], and
Scgn-positive, PKCgamma-negative dorsal horn inter-
neurons may not be excitatory [57]. We have, however,
not been able to assign these neurons to any of the cat-
egories identified in extensive developmental studies
[19,20]. They are distinctly different from those harbor-
ing the three most-studied CaBPs (PV, CB and CR).
Scgn mRNA was detected in a subpopulation of hDRG
neurons, and Scgn mRNA transcripts were found in
mDRGs by means of qPCR. The specificity of the anti-
serum has further been supported by adsorption experi-
ments and Western blot analysis, as also shown in
previous studies on brain [15,16], where results were
compared with those in the Allen brain atlas [59]. Fi-
nally, double-staining experiments with two different
antisera raised against different epitopes and in two ani-
mal species stained the same cell bodies in mDRGs.
Scgn is present in all major compartments of the mDRG
neuron
An interesting question is to what extent Scgn produced
in the mDRGs is transported to the dorsal horn. Our
findings with dorsal rhizotomy suggest that the staining
in the superficial layers, but not in inner lamina II, origi-
nates in the DRGs. Moreover, Scgn is detected in thesciatic nerve and is transported peripherally from the
cell body, as shown by the accumulation of Scgn-LI
proximal to a compression of the sciatic nerve. There-
fore, Scgn may have a function(s) not only in cell bodies
but possibly also in central and peripheral nerve
terminals.
A similar situation may exist for the other three CaBPs
discussed here, since there is a loss of CaBPs in the ipsi-
lateral dorsal column/column nucleus after unilateral,
multiple dorsal root ganglionectomy [40] and dorsal rhi-
zotomy [34]. The latter is the projection area of large
DRG neurons [62], and this is the category of DRG neu-
rons that to large extent harbor CR and PV.
Other CaBPs in DRGs
CaBPs have in mouse mainly been studied as markers for
the diverse neuron populations, especially during develop-
ment and in cultures (e.g. [19,20,28,30-32]), but detailed
in vivo quantitative and colocalization analyses of adult
mDRGs are less common. Nevertheless, Ichikawa et al.
[50] reported the presence of PV-LI in ~5% of adult
mDRG NPs.
In contrast, a large number of studies have dealt with
this issue in rat (for refs. see Introduction). In the most
recent study on rDRGs by Ichikawa and colleagues [44]
and using triple-label immunostainings, CR and PV are
both present in mostly large-sized NPs, and ~10% of the
NPs contain both CaBPs (most CR neurons contain PV
and ~40% of PV neurons contain CR). A bimodal size
curve has been earlier described for CR by the same
Figure 5 Scgn-LI in control mouse lumbar spinal cord. (a-t) Immunofluorescence micrographs of sections incubated with antiserum against
Scgn (a-g, i-t), CGRP (h, i), TRPV1 (j-j”), GRP (k, k’), PKC gamma (l, l’), CB (m, m’, r-t), PV (n, o), or/and CR (p, q). Scgn-IR fibers are seen in the
superficial dorsal horn (arrowheads in a, b) and also processes in lamina III (a, b). Scgn-IR cell bodies are present in lamina II (small-sized in c), a
few in III (d) or medial (multi-polar in e) and lateral (small-sized in f) parts of lamina IV. (g-i) Ventral horn neurons express Scgn-LI (g, i) and are
mostly CGRP-IR (arrowhead in i). Scgn-IR (j”, k’, I’; green) neurons do not express TRPV1 (j,j”), GRP (k, k’) or PKC gamma (l, l’) in dorsal horn. (m-q)
Filled Arrowheads indicate coexistence (yellow) of Scgn-LI (m’, o, q, green) and CB (m, red), PV (o; red) or CR (q; red) in the dorsal horn. (r-t)
Triple-labeling of superficial dorsal horn showing (r and r’ same section) a local neuron (light blue; filled arrowhead) coexpressing Scgn (r’; green)
and CB (r’; read), but not PV (r’; dark blue). s and t show neurons (filled arrowhead; light blue) containing Scgn (green) and CB (red), but not CR
(dark blue). Empty arrowheads indicate a dorsal horn neuron only express Scgn-LI (j'',k',l',o,q,t) or a Scgn-IR fiber (j'; green) does not overlap with
TRPV1-IR fiber (j'; red).. Scale bars indicate 200μm (a), 50 μm (b=m=n=p; c=d=e=f; g=h=i; j=k=l; j’=j”; k’=l’; m’=o=q; r=s; r’=t).
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ter being expressed in neurons of various sizes.
With regard to nociceptors, known to be small-sized
DRG neurons [51,52], none of these three CaBP popula-
tions, mostly encompassing large neurons, seem to be
extensively involved: 1% of the PV-positive NPs express
CGRP [42], colocalization of CGRP with either PV orCB is “rare” [37,38]. Nevertheless, Honda [49] reported
that 9% of CB neurons are CGRP-IR, and 7% of CR neu-
rons are substance P-positive [39]. The present results
suggest that Scgn is the major CaBP in a population of
peptidergic nociceptors in mDRGs [51,52]. Similar to
mDRGs, Scgn is also expressed in mTGs, and majority





Figure 6 Scgn-LI in mouse spinal cord and sciatic nerve after rhizotomy or nerve ligation. (a-f) Immunofluorescence micrographs of
sections incubated with antiserum against Scgn- (a,c,d,f) and CGRP- (b,c,e,f) LIs in lumbar spinal cord 10 days after unilateral, dorsal rhizotomy
(d-f). (a-f) On the contralateral side both Scgn- and CGRP-LIs are strong in the superficial dorsal horn, the former displaying two bands (arrows in a, c),
the latter filling out layers I and outer II (arrows in b,c). The merged micrograph (c) shows that the deeper band of Scgn-LI, consisting mainly of cell
bodies, essentially remains in inner lamina II, without much overlap with the CGRP-LI (d-f). There is a strong ipsilateral decrease of both Scgn-LI (cf. d, f
with a, c; arrows) and CGRP-LI (cf. e, f with b, c), compared to a contralateral side (a-c). (g-i) Scgn-LI is weekly (arrows in g, i), and CGRP more
extensively (arrow in h, i) expressed in the control sciatic nerve, and both accumulate, on the proximal side of a-10-hour ligation (arrows in j, k).
Double-staining shown in merged color micrographs indicates possible coexistence (arrows in i, l). Scale bars indicate 100 μm (a-f; g-l).
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We detected both similarities and differences in expres-
sion of Scgn-LI when comparing DRGs, TGs and spinal
cord of mouse with rat and human tissues, suggesting
partially conserved protein expression. In rDRGs, even
fewer NPs were Scgn-IR as compared to mouse and, sur-
prisingly, none of them was CGRP-IR. In contrast, Scgn
expression was quantitatively similar in mouse and
human DRGs, most of them expressing CGRP and none
seemed IB4-positive. In rTGs many Scgn-IR neurons
coexpressed CGRP and many, unexpectedly, stained for
IB4, whereas no Scgn-IB4 containing neurons were
detected in mouse TGs.
With regard to spinal cord, Scgn in mouse is present
mainly in cell bodies in inner lamina II and, albeit in low
numbers, in several other layers (I, II-IV) of the dorsal
horn, and in ventral horn neurons. This pattern was
similar in human spinal cord. However, cell bodies were
only detected in inner lamina II, and they did not form a
distinct band as in mouse. In rat, Scgn staining was less
pronounced with little fiber staining in the verysuperficial region, possibly reflecting the low numbers of
Scgn-IR cell bodies in DRGs and with the staining in
inner lamina II mainly located medially. In spinal ventral
horn, no Scgn-IR neurons could be detected in rat.
Scgn-LI in mouse was found together with CB-, PV- or
CR-LI, albeit at very different proportions. In the rat
spinal cord some Scgn-IR interneurons also expressed
CB or PV, but not CR-LI.
Taken together, mouse is similar to human with re-
spect to Scgn expression in DRGs, and to large extent in
the spinal cord, while rats exhibit substantial differences.
With regard to CaBPs, in rDRGs more than 40% of the
Scgn-IR NPs co-expressed CB, but hardly any CR or PV,
a species difference here is being the low CB-Scgn coex-
istence in mouse.
Scgn and other CaBPs in spinal cord
Several studies on CaBPs in the rat spinal cord have
been published [21,34-36,40,48,63] but only few on
mouse [29], the latter focusing on a select neuron popu-






Figure 7 Scgn -LI in control rat spinal dorsal horn. (a-f) Immunofluorescence micrographs after double-staining with antiserum against Scgn
(a,c,d,f), CGRP (b,c) or IB4 (e,f). (a-f) Scgn-IR neurons (arrows) are seen in the dorsal horn, both in superficial and deeper layers (a,d). They partly
overlap with CGRP-LI (b) and IB4 staining (e), as seen in merged color micrographs (c,f). (g-o) Double-immunofluorescence micrographs of
sections incubated with Scgn antiserum (g,i,j,l,m,o; green) plus CB (h, i; red), PV (k,l; red) or CR antiserum (n,o; red). Coexistence is often seen for
CB in cell bodies (arrows in g-i) and processes (arrowheads in g-i), less so for PV (arrow/arrowheads in j-l) and, here, none for CR (m-o). Arrows
indicate coexistence (yellow) of Scgn-LI (i, l) and CB (i) and PV (l) in the dorsal horn neurons. Arrowheads indicate coexistence of Scgn-IR fibers
(i,l) and CB (i) or PV (l). Curved arrows indicate a Scgn-positive neuron that does not express CB (g-i). Arrows indicate a CR-positive but Scgn
negative neuron (m-o). Bar in f indicates 100 μm (a-f) and 50 μm (g-o).
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are CB-IR, fewer CR-IR and none PV-IR. In lamina II
CB- and CR-IR neurons are densely packed, and PV is
confined to a distinct band in inner lamina II. There is
only limited coexistence of the three CaBPs in the super-
ficial laminae, although examples of cell positive for both
CR and CB have been observed [40]. Laminae III and IV
have in general cell bodies expressing CaBPs [35,48]. In
the present study Scgn was, in contrast to CB, CR and
PV, also expressed in mouse ventral horn neurons.Functional aspects on Scgn
In view of their function as ‘gate keepers’ of Ca2+ homeo-
stasis, CaBPs have been hypothesized a protective role for
preventing abnormal, cytotoxic Ca2+ levels, thus likely
participating in neurodegenerative processes and disease
[64-72]. Interestingly, involvement of Scgn in neuronal
survival in Alzheimer’s disease has also been reported
[10-12]. There is functional evidence that Ca2+ buffering is
important also in sensory neurons [73] and its dysfunction
































Figure 8 Expression of Scgn protein after sciatic nerve axotomy as shown with western blot. (a, b) L4-5 DRGs (a) and L 4–5 spinal cord
segments (b) after unilateral nerve transection using antiserum against Scgn and β-Actin. No obvious changes in Scgn expression are seen in ipsi-
and contralateral DRGs (a) or spinal cord (b), respectively. Quantification of three western blots shows similar levels of Scgn between ipsi- and
contralateral DRGs or spinal cord.
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for Scgn in DRG neurons, since an interaction between
Scgn and SNAP-25 proteins has been reported by Rogstam
et al. [17]. This finding suggests a role in the control of
neurotransmitter release since N-ethylmaleimide-sensitive
factor-attachment protein receptors (SNAREs)-associated
proteins are part of the exocytotic machinery [18]. Inter-
estingly, inhibition of exocytosis causes long-lasting at-
tenuation of pain [75].
Conclusions
Scgn represents a novel CaBP, which here and earlier
has been found expressed in subpopulations of neurons
in the rodent and primate nervous system, complemen-
tary to several other well-known members of this pro-
teins superfamily. However, Scgn-positive DRG neurons,
presumably a subtype of nociceptors both in mouse and
humans, do not seem to perfectly match any of the DRG
neuron populations identified during development in
mice [19,20]. Scgn is also present in cell bodies in vari-
ous layers of the dorsal horn. Analysis of corresponding
tissues in rat suggests species differences in Scgn expres-
sion. The similarity between mouse and human DRGs
suggest that results from future experiments on Scgn, e.
g. using gentically modified mice, may be relevant to de-
cipher molecular pathomechanisms in humans.
Methods
Tissues and animal models
Experiments were performed on male C57BL/6J Bommince
mice (A/S Bomholtgaard, Ry, Denmark) weighing 25–28 g,
and on adult male Sprague–Dawley rats (200–250 g; B and
K Universal, Stockholm, Sweden). All animals were kept
under standard conditions on a 12-hour daylight cycle with
free access to food and water. Unilateral sciatic nervetransection (axotomy) was made on n=10 mice as
described earlier [76]. Surgical procedures were performed
under anesthesia with isoflurane. Operated animals were
allowed to survive for 2 weeks after surgery. Dorsal root
rhizotomy was done on n=5 mice, and animals were
allowed to survive for 10 days. Sciatic nerve ligation was
done in n=5 mice, which were sacrificed after 10 hours.
Human ganglia were harvested from children with obstetric
brachial plexus lesions, and undergoing reconstructive
nerve surgery. Human spinal cord was harvested from a
48-year-old women died from stroke. The studies have
been approved by the local Ethical Committee for animal
experiments (Norra Stockholms djursförsöksetiska nämnd),
and experiments on hDRGs were approved by a local Eth-
ical Committee with written consent from the next of kin.
mRNA detection in tissues
In situ hybridization analysis of Scgn mRNA in mouse
olfactory bulbs using riboprobes was performed as previ-
ously described [77]. Briefly, adult brains were perfusion
fixed followed by post-fixation in the same fixative over-
night (4% paraformaldehyde, in 0.1M PB), cryoprotected
(30% sucrose in 0.1M PB), embedded in Tissue-tek OCT
compound (Miles Laboratories, Elkhart, IN) and sec-
tioned at a thickness of 20 μm. The fragment of scgn
cDNA used for riboprobe synthesis was amplified from
an adult mouse olfactory bulb cDNA preparation by PCR
using Pfu DNA polymerase (Promega). The primers used
for scgn cDNA amplification were flanked at their 5’ ends
with T7 and SP6 polymerase acceptors 5’-[CTGTAATAC
GACTCACTATAGGG] TCTCTAAGGAAGGCCGCATA
-3’ (sense) and 5’- [GGGATTTAGGTGACACTATAGA]
AGACACAGTGCCAGCTCAGA -3’ (antisense). Result-
ing amplicons were directly used as templates for in vitro
transcription. Amplicon size was confirmed by loading
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antisense and sense riboprobes for mouse scgn were
synthesized by in vitro transcription using SP6 and T7
RNA polymerases (Roche). After synthesis, probes were
cleaned by using the RNeasy kit (Qiagen) and DNA
digested with RNase-free DNase I (Qiagen). Alkaline
phosphatase-conjugated anti-digoxigenin antibodies
(Roche, 1:2,000) were used with their signal developed
by 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue
tetrazolium as substrate (BCIP/NBT; Roche).
In situ hybridization using oligoprobes was performed
as described previously [78]. Briefly, a mixture of two
commercially acquired oligonucleotide probes (Cyber-
Gene, Stockholm, Sweden, or MWG Biotech, Ebersberg,
Germany) were used: 1) GGACAGGCAGAGCCATC
TAACAGGGGAG, 2)ACACAGGGGCTTTCAGTGAG
ACAGGGATAGAT complementary to nucleotide
sequences of the human Scgn (accession number
NM_006998.3). hDRGs were air-dried and incubated
with a hybridization solution containing 0.5 ng of la-
beled probe/slide. The hybridization solution contained
50% deionized formamide (J.T. Baker Chemicals,
Deventer, The Netherlands), 4×SSC (0.6 M sodium
chloride, 0.06 M sodium citrate), 1× Denhardt’s solution
(0.02% bovine serum albumin, 0.02% Ficoll (Pharmacia,
Uppsala, Sweden), 0.02% polyvinylpyrrolidone), 1%
N-lauroylsarcosine, 0.02 MNaPO4 (pH 7.0), 10% dex-
tran sulfate (Pharmacia), 500 μg/ml denatured salmon
testis DNA (Sigma, St. Louis, MO, USA) and 200 mM
dithiothreitol (LKB, Stockholm, Sweden). Sixteen hours
after incubation the tissues were rinsed in 1×SSC for 4
times (each time 15 minutes) at 56°C and allowed to
cool to RT, washed in distilled water, and transferred
rapidly through 60% and 95% ethanol. The 33 P-dATP-
labeled sections were apposed to β-max autoradiog-
raphy film (Amersham). The films were exposed for one
and half months and developed with Kodak LX 24 and
fixed with Kodak AL4. The slides were rinsed in distilled
water and coverslipped with glycerol. The sections were
then counterstained with cresyl violet, dehydrated in
graded series of ethanol, and coverslipped with Entellan
(Merck, Darmstadt, Germany). All sections were exam-
ined in a Nikon Microphot microscope equipped for
bright- and dark-field microscopy. Photographs were
taken with a Nikon Coolpix 5000 digital camera (Nikon,
Tokyo, Japan).
mRNA detection by quantitative real-time PCR
Quantitative PCR (qPCR) reactions were performed with
custom designed primers according to published protocols
[16]. RNA isolated from tissues microdissected from adult
C57Bl/6N mice (n = 3/DRG/spinal cord/olfactory bulb)
were subjected to Scgn expression analysis after validating
RNA integrity (data not shown). Gapdh was used tonormalize Scgn mRNA expression levels. Results from
qPCR experiments were subsequently compared to Scgn
mRNA distribution as determined by in situ hybridization
(primers: 5’CCCAGAAGTGGATGGATTTG 3’; reverse:
5’GTTGGGGATCAGGGGTTTAT 3’.
Immunohistochemistry
All operated (n=20) and control mice (n=10), as well as
rats (n=10) were deeply anesthetized with sodium pento-
barbital (10 mg/kg for mouse and 50 mg/kg for rat, both
i.p.) and transcardially perfused with 20 ml (50 ml) of
warm saline (0.9%; 37°C), followed by 20 ml (50 ml) of a
warm mixture of 4% paraformaldehyde (37°C) and 0.4%
picric acid in 0.16 M phosphate buffer (pH 7.2), and
then by 50 ml (250 ml) of the same, but ice-cold fixative
[79,80]. The L 5 mDRGs, mTGs, rDRGs and rTGs, as
well as the L4 and L5 segments of both mouse and rat
spinal cord were dissected out and postfixed in the same
fixative for 90 min at 4°C. Specimens were subsequently
stored in 10% sucrose in phosphate buffered saline (PBS,
0.1 M, pH 7.4) containing 0.01% sodium azide (Sigma,
St. Louis, MO) and 0.02% bacitracin (Sigma) as preser-
vatives at 4°C for 2 days. The hDRGs and spinal cord
were immersion-fixed for four hours in ice-cold fixative
and rinsed as mentioned above. Tissues were embedded
with OCT compound (Tissue Tek), frozen and cut in a
cryostat (Microm, Heidelberg, Germany) at 10 μm
(mDRGs), 14 μm (mTGs, rDRGs and hDRGs) or 20 μm
(mouse, rat and human spinal cords) thickness and
mounted onto chrome-alum-gelatin-coated slides.
Thaw-mounted sections were dried at room temperature
(RT) for 30 min and rinsed with PBS for 15 min. Sec-
tions were incubated for 18 hours at 4°C in a humid
chamber with rabbit anti-Scgn antiserum (1:1,000);
[15,16,60] diluted in PBS containing 0.2% (w/v) bovine
serum albumin and 0.03% Triton X-100 (Sigma). In
addition a monospecific polyclonal rabbit anti-human
Scgn antibody was used [8]. Briefly, purified recombin-
ant Scgn (540 μg) was emulsified in complete Freund's
adjuvant and injected subcutaneously into a rabbit fol-
lowed by two more injections of incomplete Freund's ad-
juvant. Serum collected one month after the third
immunization contained high titer antibody activity
against the recombinant protein when tested by ELISA
[8].
Immunoreactivity was visualized using the tyramide
signal amplification system (TSA Plus; NEN Life Science
Products, Boston, MA). Briefly, the slides were rinsed
with TNT buffer (0.1M Tris–HCl, pH 7.5; 0.15 M NaCl;
0.05% Tween 20) for 15 min at RT, blocked with TNB
buffer (0.1M Tris–HCl; pH 7.5; 0.15M NaCl; 0.5%
DuPont blocking reagent) for 30 min at RT followed by
a 30-min incubation with horseradish peroxidase-labeled
swine anti-rabbit antibody (1:200; Dako, Copenhagen,
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(15 min) in TNT buffer, all sections were exposed to
biotinyl tyramide-fluorescein (1:100) diluted in amplifi-
cation diluent for approximately 15 min, and finally
washed in TNT buffer for 30 min at RT.
For double-staining experiments, immunohistochem-
istry was carried out with cocktails of primary anti-
bodies: Scgn (1:1,000) plus CGRP (1:10,000) [81], PV
(1:400), CB (1:400), CR (1:400), TRPV1(1:500) (St. Cruz
Biotechnology, St. Cruz, CA), GRP (1:500) (ImmunoS-
tar, Hudson, WI) or PKCgamma (1:1,000) (St. Cruz Bio-
technology), respectively, following previous published
protocols [60] (the three antibodies to CaBPs were from
Swant, Bellinzona, Switzerland). For triple stainings,
Scgn (1:1,000) plus PV (1:400) and CB (1:400) or Scgn
(1:1,000) plus CB (1:400) and CR (1:400). In addition, a
group of Scgn-labeled sections was incubated with the
IB4 from Griffonia simplicifolia I (GSA I; IB4; 2.5 μg/ml;
Vector Laboratories, Burlingame, CA) [82] followed by
incubation with a goat anti-GSA I antiserum (1:4,000;
Vector Laboratories) and rhodamine red X-conjugated
donkey anti-goat antibody (1:200; Jackson ImmunoRe-
search, West Grove, PA). hDRG slides were only pro-
cessed for Scgn and CGRP or IB4, respectively. Finally,
all slides were coverslipped with glycerol/PBS (9:1) con-
taining 2.5% DABCO (Sigma) [83,84].
The specificity of Scgn antiserum was tested by preab-
sorption of the antiserum with homologous antigen at a
concentration of 1 and/or 10 μM for 24 hours at 4°C.
After incubation with control serum, i.e. Scgn antiserum
pre-absorbed with the excess of Scgn, no fluorescent
neuronal cells could be observed (data not shown).
Western blot analysis
L4 and L5 mDRGs from mice with unilateral sciatic
nerve transection (n=5) and controls (n=5) were
removed and immediately put on dry ice. DRGs and
spinal cord (L4-5 segments) were homogenized in lysis
buffer (50 mM Tris–HCl, pH 7.4, 1% NP-40, 0.25% so-
dium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
NaF and 1 mM Na3VO4) containing protease inhibitor
cocktail (Sigma) using sonication. Lysates were centri-
fuged at 12,000 rpm for 20 min at 4°C. The supernatant
was collected for western blots. Protein concentration
was measured by Bradford’s Assay (Bio-Rad, Hercules,
CA). Laemmeli sample buffer containing about 20 μg of
protein was loaded in each lane and separated on 10%
SDS-PAGE gel, then transferred to polyvinylidene fluoride
(PVDF) membranes (Millipore, Hemel, Hempstead, UK).
The membranes were blocked with 5% non-fat dry milk
in PBS with 0.1% Tween-20 for 1 hour at RT and incu-
bated overnight at 4°C with an antibody against Scgn
(for DRG sample, rabbit polyclonal, 1:1,000; for spinal
cord sample, mouse monoclonal, 1:1,000; Atlas antibodyclone 13B8). The membranes were incubated with
HRP-conjugated secondary antibodies for 1 hour at RT
(1: 5,000-1: 10,000, DAKO) followed by ECL solution for
5 min (Amersham Biosciences, Piscataway, NJ) and
exposed to X-ray film (NEN PerkinElmer, Waltham, MA).
The membrane was stripped and re-probed for β-Actin
(mouse monoclonal, 1: 5,000-10,000, Cell Signaling Tech-
nology, Danvers, MA) as loading control. Images were
quantified with Quantity One software on non-saturated
images (Bio-Rad).Image analysis and quantification
Specimens were analyzed on a Bio-Rad Radiance Plus con-
focal scanning microscope (Bio-Rad, Hemel, Hempstead,
UK) installed on a Nikon Eclipse E 600 fluorescence
microscope (Nikon, Tokyo, Japan) equipped with x10
(0.5 numerical aperture, NA), x20 (0.75 NA) and x60 oil
(1.40 NA) objectives. Fluorescein labeling was excited
using the 488-nm line of the argon ion laser and detected
after passing a HQ 530/60 (Bio-Rad) emission filter. For
the detection of lissamine rhodamine sulfonyl chloride
and rhodamine, the 543-nm HeNe laser was used in com-
bination with the HQ 570 (Bio-Rad) emission filter. For
the detection of DAPI a 405-nm laser was used. All the
slides were scanned in a series of 1μm-thick optical sec-
tions. Consequently, images were analyzed separately and
merged to evaluate possible colocalization. In some cases
a Zeiss laser scanning microscope 780 system with a plan-
apochromat x 20 (0.8NA) M27 objective was used.
To determine the percentage of IR NPs, the counting
was performed on 10 or 14 μm thick sections, and
every 4th or 6th section was selected (Nike Microphot-
FX microscope, 20x objectives). The total number of
immuno-positive NPs was divided by the total number
of propidium iodide-stained [85] NPs in the DRG sec-
tions, and the percentage of positive NPs was calcu-
lated. Five to ten sections of each DRG from five
animals in each group were included in the analysis,
and 1,200-3,000 NPs were counted in each ganglion.
The size distribution of NPs with a visible nucleus was
measured using the Nikon Eclipse E 600 fluorescence
microscope with Wasabi Image Software. We divided
the NPs into small (a somal area of 100–600 μm2);
medium-sized (600–1400 μm2) and large (>1400 μm2)
according to earlier studies [76,86]. The percentages of
DRG NPs in each of these categories were calculated.Statistical analyses
Differences between the percentage of Scgn-IR NPs as
well as the gray levels of Scgn in mDRG neurons in ip-
silateral and contralateral samples were evaluated by
Student’s t test.
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Additional file 1: Figure S1. (A) Overview of in situ hybridization to
detect Scgn mRNA in the adult mouse olfactory bulb using a riboprobe.
Open rectangles indicate the locations of (A1,A2). (A1) Cellular Scgn
mRNA detection (arrowheads) in the external plexiform layer (ML: mitral
cells are negative). (A2) Hybridization signal, although at markedly lower
levels, is also seen in periglomerular cells (arrowheads). (B) Sense control
showing the lack of non-specific signal detection/amplification. (C)
Immunohistochemistry for Scgn (red) in the mouse olfactory bulb. Note
that layer-specific cellular immunoreactivity confirms mRNA distribution.
CR (blue) is used to identify the glomerular layer. (C1) High-resolution
image of neurons at locations corresponding to that in (A1, arrowheads).
Abbreviations: EPL, external plexiform layer; GL, glomerular layer; GRL,
granular layer; ML, mitral layer Scale bars = 200 um (A,B), 100 um (C), 10
um (A1,A2,C1).Abbreviations
CaBP: Calcium-binding protein; CB: Calbindin D-28k; CGRP: Calcitonin gene-
related peptide; CR: Calretinin; GRP: Gastrin releasing peptide; m/r/
hDRG: Mouse/rat/human dorsal root ganglion; IB4: Isolectin B4;
IR: Immunoreactive; L: Lumbar; LI: Like immunoreactivity; NP: Neuron profile;
PKCgamma: Protein kinase C gamma; PV: Parvalbumin; RT: Room
temperature; Scgn: Secretagogin; TG: Trigeminal ganglion; TRPV1: Transient
receptor potential vanilloid subtype 1.
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